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Toward Targeted
Hypertension Screening Guidelines
Stef van Buuren, PhD, Hendriek C. Boshuizen, PhD, Sijmen A. Reijneveld, MD
Background. Guidelines for screening and subsequent treat-
ment of hypertension vary widely between countries. Part of
this variation can be attributed to systematic differences be-
tweenpopulations, but little is knownabout theway inwhich
guidelines should be targeted to the population of interest.
Optimal guidelines should have high yield and low complex-
ity. The goal is to fit procedures for screening and subsequent
treatment of hypertension optimally to a specific population.
Methods.Simulation studyon individual cardiovascular risk
profiles, with drug treatment altering the 10-year cardiovas-
cular risk. The analysis compares the consequences of vari-
ous screening and treatment alternatives. The reference sce-
nario consists of the Dutch hypertension guidelines for
primary care. A representative sample of the Dutch popula-
tion aged 20 years and older is taken as the target. Main out-
comemeasures include incidence, quality-adjusted life years
won, number needed to screen, and costs (prevention, mor-
bidity, andmortality). The discount rate is 4%.Results.Strict
adherence to the current hypertension guidelines saves costs
(i.e., the total prevention costs are less than the costs of pre-
vented morbidity and mortality). The following changes in-
crease its cost-effectiveness: use of lower blood pressure lev-
els for screening and treatment, reduction of the number of
screens from 5 to 3, and active call-up of high-risk patients.
The adherence to guidelines has a large influence on actual
cost-effectiveness achieved in practice. Conclusions.Appro-
priate targeting of hypertension guidelines to a population
and critical appraisal of the entire screening procedure can
enhance cost-effectiveness. Key words: hypertension; risk
factors; mass screening; practice guideline; guideline adher-
ence; health care costs. (Med Decis Making 2006;26:145–
153)
T reatment of hypertension reduces risks of cardio-vascular disease and thus yields future health
gains. Over the past decade, expert committees in
many countries developed guidelines for screening
and treatment of those at high risk. Important discrep-
ancies between these recommendations have, how-
ever, been signaled.1–4 Recommendations seriously di-
verge on the levels of blood pressure (BP) that define
hypertension. Also, they vary in the set of risk factors
that must be taken into account, the number of visits
needed for diagnosis, the age at which to start screen-
ing, the minimum BP level that justifies drug treat-
ment, the therapeutic objectives, and so on.
Following the classic work of Stason and
Weinstein,5 cost-effectiveness of hypertension treat-
ment has been studiedquite extensively.6–10 The results
from these studies are extremely helpful in making
clinical guidelines more evidence based. Screening
has attracted less attention, however. Published guide-
lines are usually very brief on screening, and little sys-
tematic research on appropriate screening strategies is
available. Ramsey and others2 highlighted the role of
the absolute cardiovascular risk of the population in
the context, but most cost-effectiveness studies do not
account for the population risk. The implication is that
cost-effectiveness of the same screening strategy may
vary dramatically with the risk of the population. Fur-
thermore, it is common practice to screen patients for
MEDICAL DECISION MAKING/MAR–APR 2006 145
Received 17 March 2004 from TNOQuality of Life, Leiden, the Nether-
lands, and the Department of Methodology and Statistics, University of
Utrecht, the Netherlands (SvB); National Institute of Public Health and
the Environment (RIVM), Bilthoven, the Netherlands (HCB); and TNO
Quality of Life, Leiden, the Netherlands, and the Department of Health
Sciences, Northern Centre for Healthcare Research, University of
Groningen, the Netherlands (SAR). Financial support for this study was
provided in part by a grant from ZorgOnderzoek Nederland, The
Hague. The funding agreement ensured the authors’ independence in
designing the study, interpreting the data, and writing and publishing
the report. The authors are very grateful to P. C. W. van den Hoogen
(RIVM, Bilthoven), J. C. M. Witteman, and B. van Hout (Erasmus Uni-
versity, Rotterdam) for their help and supply of data. They also thank A.
van Drenth, J. A. H. Eekhof, B. D. Frijling, E. P. Walma, and T. van der
Weijden for their supervision. The study was financially supported by
ZorgOnderzoek Nederland (ZonMw), The Hague, grant 22000023.
Revision accepted for publication 2 October 2005.
Address correspondence and reprint requests to Stef van Buuren,
TNO Quality of Life, PO Box 2215, 2301 CE Leiden, the Netherlands;
e-mail: S.vanBuuren@pg.tno.nl.
DOI: 10.1177/0272989X06286479
having cardiovascular risk factors, which widely vary
in both prevalence and associated risks. Thus, selection
and exclusion may highly affect cost-effectiveness. Fi-
nally, little is known about the impact of choices made
in the screening procedure on cost-effectiveness, such
as the number of screens needed for diagnosis, the age
at which screening should start, and appropriate BP
cutoff levels for best cost-effectiveness.
This study presents the results of an approach to fill
these gaps. Our approach accounts for the risk factor
distribution in the population of interest and enables
us to study the influence of different screening alterna-
tives on cost-effectiveness. We applied our method to
the Dutch population, aged 20 years and older, depart-
ing from Dutch hypertension guidelines.11 This is one
of the few guidelines that contains a relatively detailed
screening protocol.More specifically, we concentrated
on 2 questions: Are the current hypertension guide-
lines cost-effective for the population of interest? Is it




Wedeveloped a simulationmodel that enabledus to
define variations on the published guidelines, called
scenarios. Each scenario was applied to a representa-
tive sample of persons from the population of interest.
The cardiovascular risk profile of each person was
known.
Cardiovascular risk factor data on theDutchpopula-
tion were available from the MORGEN study12 (ages
20–59,n=13,742, collected in1995–1997) and theRot-
terdam study13 (ages 55+, n = 7983, collected in 1990–
1993). Measurements include systolic (SBP) and dia-
stolic (DBP) blood pressure, low-density lipoprotein
(LDL)/high-density lipoprotein (HDL) ratio, diabetes,
cardiovascularhistory, familial cardiovasculardisease,
left-ventricular hypertrophy, smoking, body mass in-
dex (BMI), and use of alcohol. We drew a resample of
11,983 people from the combined data such that age
and sex distributions corresponded to the Dutch popu-
lation of 20 years or older per 1 January 2000. Each per-
son in the simulation sample thus corresponded to
1000 real people in the population. The appendix
describes some practical data problems that had to be
dealt with.
The model computes the 10-year absolute coronary
risks for 7 events: death by coronary heart disease
(CHD), death by other cardiovascular disease (CVD),
death bynon-CVD,myocardial infarct (MI), otherCHD,
stroke, and other CVD. In linewith otherwork,14 the in-
cidence rates predicted by the equations from the
FraminghamHeart Study15were generally very close to
Dutch incidence data. Some minor adjustments were
needed for the older age groups, in which the
Framingham predictions were often too low (see the
appendix for more details). We assumed that
antihypertensive drug treatment induces proportional
reductions in the absolute risk that varies between
13.7% (for CHDmortality) and 34.3% (for stroke)16 (see
the appendix for more details).
BPmeasurementswere randomly simulatedunder a
statistical model for blood pressure variation, similar
to the model used by Rosner and Polk.17 The mean of
the distribution from which measurements were
drawn depended on the set of risk factors particular to
the person. The variance of the distribution consisted
of 4 components: between persons (variances SBP:
400.5,DBP: 94.1), betweenvisits (variancesSBP: 105.6,
DBP: 23.7), between doctors (variances SBP: 6.1, DBP:
5.1), andwithin visits (variances SBP: 26.0, DBP: 16.3).
More details about the BPmodel and the estimates can
be found elsewhere.18
Costs and Health Effects
Costswere estimated for screening, preventive treat-
ment, mortality, andmorbidity. Screening and preven-
tive treatment occur in a primary care setting. Screen-
ing costsdependon thenumber of patient visits, the fee
per visit (€18.15), and laboratory costs (€11.34 per case).
The fee per visit and the laboratory costswere based on
the actual reimbursement scheme of the Dutch health
system. Costs of antihypertensive treatment were equal
to €190.59 per year per treated patient.19 Estimates of
morbidity andmortality costswere taken fromVanHout
and others10 and are given in the appendix. The same
estimates have beenused to assess cost-effectiveness of
the Dutch cholesterol guidelines.10 Costs are reported
in euros (€) per person (in the population) per year
(pppy) in prices of the year 2000. Prices of previous
years were corrected for inflation to 1 January 2000 us-
ing the official inflation rates as published by theNeth-
erlands Bureau of Statistics. Total yearly costs on the
population level were found by multiplying estimates
made in terms of “€ pppy” by a constant 11,983,000,
the size of the population aged 20 years and older. An
expert committee reviewed all cost estimates used
within the project.
The following health outcomes were estimated un-
der each scenario: incidences (for all 7 risk events),
number needed to screen (NNS) andnumber needed to
treat (NNT) to prevent 1 cardiovascular event,20 life
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years gained, quality-adjusted life years (QALY)
gained, and healthy life years gained. Utility values for
theQALY calculationswere taken from the literature.21
The appendix details how these are calculated.
Screening took place during the 1st year. We as-
sumed that drug treatment, if indicated, lasted for the
full 10 years and only stopped if the patient died. The
official Dutch discount rate of 4% was used to adjust
for time preference in both costs and health.22 To elimi-
nate the influence of tiny improvements among many
people with normal blood pressure, life year measures
were calculated under the assumption that drug treat-
ment has no effect below a sustained blood pressure
level of SBP <160 mm Hg and DBP <90 mm Hg.
Analysis
The starting model was based on the Dutch hyper-
tension guidelines. The guidelines define hyperten-
sion as sustainedSBP>160mmHgorDBP>95mmHg.
The screening protocol is as follows. The general prac-
titioner should measure the BP of all visiting patients
with an increased cardiovascular risk. This concerns
patientswith 1 of the following screening factors: diabe-
tesmellitus, previous CHD, older than 60 years, familial
CVD, indication for cholesterol treatment, or earlierhy-
pertension. If the initial BP is above 160/95 mm Hg,
then BP should bemeasured during 3 additional visits.
If either the average SBP is <160 and DBP is <95, or if
DBP is >105, no further measurements are taken. Two
additional visits are scheduled for the remaining
group.Drug treatment is indicated ifmeanDBP>105or
meanSBP>180mmHg. If 1 ormore additional risk fac-
tors (high cholesterol, diabetes mellitus, smoking, or-
gan damage, familial CVD, age >60, male) are present,
drug treatment is indicated if DBP >100 or SBP >160.
After appropriate titration of dosage, control visits have
to occur once every3months. Patientswithknownand
treated hypertension do not enter the screening. Only
patients who visit the general practitioner are mea-
sured; there is no active call-up.
We first assessed the effect of the Dutch guidelines
(scenario “basic”) compared to the situation in which
the entrance of all new cases stopped but known cases
continued treatment (scenario “freeze”). Comparing
scenarios “basic” and “freeze” provides evidence
about the cost-effectiveness of the Dutch guidelines
compared to doing nothing. Although the “freeze” sce-
nario is unlikely to occur inpractice, it provides anatu-
ral null for the health effect measures and screening
costs. The comparisons of real interest are between the
“basic” scenario and simple variations in the guide-
lines, as defined in Table 1. This comparison yields in-
sight into the performance of separate components of
the current guidelines. Many aspects of the results can
be inspected. To be concise, the Results section focuses
on the QALYs gained under each scenario. The QALY
summarizes effects on bothmortality andmorbidity by
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Table 1 Overview of Variations (Scenarios) on the Dutch Guidelines
Scenario Description
basic Basic scenario: screening and treatment according to the Dutch guidelines
freeze No further screening and case finding (null model)
50+ Lowers the minimal screening age to 50
55+ Lowers the minimal screening age to 55
65+ Increases the minimal screening age to 65
-dia Eliminates diabetes as an entrance criterion
-fam Eliminates familial cardiovascular disease as an entrance criterion
-his Eliminates earlier cardiovascular history as an entrance criterion
+bmi Adds body mass index ≥30 as an entrance criterion
+smo Adds smoking as an entrance criterion
+alc Adds daily use of alcohol as an entrance criterion
active Actively calls up patients satisfying entrance criteria to entrance consult
any Ignores any entrance criteria, measures blood pressure (BP) of all patients attending the consult
3visits Lowers the maximum number of follow-up consults from 5 to 3
E150/90 Lowers the BP criterion for follow-up measurements 1 to 3 from 160/95 to 150/90
E140/85 Lowers the BP criterion for follow-up measurements 1 to 3 from 160/95 to 140/85
V150/90 Lowers the BP criterion for follow-up measurements 4 and 5 from 160/95 to 150/90
I160/95 Lowers the BP criterion for drug treatment without risk factors from 180/105 to 160/95
combining the length of life and utility (i.e., quality) of
the life years concerned.
Inpractice, adherence to the guidelines is imperfect,
which could influence the actual cost-effectiveness
seen in practice. To study the impact of imperfect ad-
herence, we conducted additional analyses in which
persons indicated for treatment were randomly as-
signed to the nontreatment group (under-treatment),
andpersonsnot indicated for treatmentwere randomly
assigned to the treatment group (over-treatment).
RESULTS
Figure 1 is a graphic representation of the screening
procedure according to the Dutch guidelines. The fig-
ure portrays the flow of the Dutch population age 20
years and older on 1 January 2000 through this proce-
dure. Screening and detection of hypertension consist
of 6 steps, represented in the central column of Figure
1. At the end of the screening year, the outcome (indi-
cated for treatment, yes/no) is known for every popula-
tion member. The total number of new cases indicated
for drug treatment is equal to 34,000 + 249,000 =
283,000, or about 2.4% of the population.
Table 2 presents incidence rates, costs, and health
effects of the Dutch guidelines (“basic”) compared
with doing nothing (“freeze”). According to the table,
prevention decreased the total yearly cardiovascular
morbidity by about 2314 new cases (1.8% of the total
morbidity), particularly through a reduced incidence
of stroke. The number of deaths decreased by 1052 per
year, or about 0.7% of the all-causemortality. For com-
parison, this is similar to the yearly number of traffic
deaths in the Netherlands. The total number of life
years gained for treating the283,000patientsdenovo is
equal to 63,968 years (undiscounted 95,216 years),
which corresponds to 3 months of additional life ex-
pectancyper treatedpatient. Gains inQALYs (110,964)
are larger because the effect of drug treatment on mor-
bidity is larger than on mortality.23 The total costs un-
der the basic scenario were estimated as €264.26 pppy,
or about €3.17 billionper year for the population age 20
and older. Stopping all screening activities lowered
prevention costs by €6.40 pppy (= 0.81 + 5.59). How-
ever, as more disease occurred, morbidity costs with-
out prevention were €7.10 pppy (= 6.92 + 0.18). Thus,
prevention through strict adherence to the guidelines
pays for itself and comes with a positive balance of
€0.70pppy.The increased (healthy) life expectancy is a
bonus.
The 2nd question is how the current guidelines can
be improved. Figure 2 plots the QALYs gained against
the costs. Observe that the variations in costs are very
small (within 1%), whereas differences in health out-
comes vary bymore than 40%. Themost cost-effective
scenarios are located in the upper-left corner. Scenario
“active,” which involves an active approach of poten-
tial high-risk patients, had the most favorable cost-
effectiveness ratio and in fact dominates the basic
scenario. Other scenarios that improved the cost-
effectiveness (compared to the current guidelines) con-
cern a lowering of the BP critical cutoff levels for
follow-up or treatment (E140/85, E150/90, V150/90,
I160/95). Thus, the level for the entrance visit in the
current guidelinesmaybe toohigh.Reducing themaxi-
mum number of follow-up visits from 5 to 3 could be
donewithout adverse effects andevenslightly improves
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SBP≥160 or 95≤DBP<105SBP<160 and DBP<95
SBP<160 and DBP<95
Figure 1 Flowdiagram for hypertension screening according to the
current Dutch hypertension guidelines (numbers are in thousands).
a. Screening criteria: diabetes, previous CHD, age > 60, familial CVD, high
cholesterol, history of hypertension.
b. Treatment criteria: DBP ≥ 105, SBP ≥ 180, 160 ≤ SBP < 180 with risk fac-
tor, 100 ≤ SBP < 105 with risk factor. Risk factors are: high cholesterol, dia-
betes, smoking, organ damage, familial CVD, age > 60, male.
upon cost-effectiveness. A reduction in the number of
visits would simplify the lower part of the flowchart in
Figure 1. Using risk factors (obesity, smoking, or alco-
hol) as additional entrance criteria also improvedeffec-
tivenessbut at increasing costs. It is generallymore effi-
cient to lower the age at which screening should start.
Compared to other scenarios, it was not cost-effective
tomeasure the BP of all patients, regardless of age,who
visit the general practitioner (scenario “any”). Using
(healthy) life years instead of QALYs led to similar
findings.
Combining the best scenarios from Figure 2 yielded
additional benefits. Compared to the basic scenario,we
found that 1) lowering the entrance criterion from160/95
to 140/85 and 2) using only 3 follow-up visits slightly
reduced costs (€264.21 pppy instead of €264.25 pppy)
and substantially increased QALYs won (138,800 in-
stead 110,964). Thus, the combination of 2 simple al-
terations led to a much better screening method. If, in
addition, the criterion for drug treatment for patients
with no extra risk factors was lowered from 180/105
mmHg to 160/100 mmHg, then the number of QALYs
won increased to 167,000 at slightly higher costs
(€264.85 pppy). Combining this with the scenario “ac-
tive” boosted cost-effectiveness even further (197,400
QALYs, €265.48 pppy). These results demonstrate that
(much) larger health benefits are possible than
achieved with the current guidelines, at only small in-
creases in costs.
We conducted an additional analysis in which we
randomly assigned 50% of the group with high BP to
the nontreatment group. The realized health gains
were approximately only half of the potential gains at
almost equal costs. Over-treatment led to the opposite
effect. We took a random sample of 5% of the popula-
tion that was not indicated for drug treatment and as-
sumed that this group was treated with BP-lowering
drugs. The health benefits of treating this group were
relatively small, but the costs increased dramatically.
DISCUSSION
Are the Dutch hypertension guidelines cost-effective?
Canwe improve on the cost-effectiveness of the guide-
SIMULATION IN CARDIOVASCULAR DISEASE PREVENTION 149
TARGETED HYPERTENSION SCREENING
Table 2 Estimated Absolute Incidences, Health
Effects, and Costs in the Dutch Population 20 Years
and Older (N = 11,983,000) under Scenarios “Freeze”
(Stop All Screening Activities) and “Basic”
(Strict Adherence to the Current Guidelines)
Scenario
Outcome Freeze Basic Difference
Incidence (events per year)
Myocardial infarct 26,304 25,942 362
Other coronary heart disease
(CHD) 15,752 15,624 128
Stroke 31,627 30,310 1317
Other cardiovascular disease
(CVD) 54,402 53,895 507
Total morbidity 128,085 125,771 2314
Mortality by CHD 27,980 27,578 402
Mortality by other CVD 21,130 20,480 650
Non-CVD mortality 101,371 101,371 0a
Total mortality 150,481 149,429 1052
Health effects
Number needed to screen
(NNS) morbidity ∞a 503.0
Number needed to treat (NNT)
morbidity ∞a 12.1
Life years gained 0a 63,968
Quality-adjusted life years
(QALYs) gained 0a 110,964
Healthy life years gained 0a 174,684
Costs (in euros per person
age 20 and older per year)
Screening 0 0.81 –0.81
Treatment and control 17.59 23.18 –5.59
Cardiovascular morbidity 233.21 226.29 6.92
Cardiovascular mortality 14.17 13.99 0.18
Total cost 264.96 264.26 0.70
a. By definition.
QALY’s gained (in thousands)















































Figure 2 Total quality-adjusted life years (QALYs) gained in the
Dutch population age 20 and older plotted against the total costs (in
eurosperpersonper year). SeeTable1 for abbreviationsof scenarios.
lines and, if so, at what points? We found that strict
adherence to the guidelines is a cost-effective way of
preventing cardiovascular disease. Substantial im-
provements can be achieved by altering specific
screening and treatment criteria. In particular, the fol-
lowing changes increase the cost-effectiveness for the
Dutch population age 20 years and older: use of lower
blood pressure levels for screening and treatment, re-
duction of the number of consults from 5 to 3, and ac-
tive call-up of high-risk patients.
Although the analyses done with respect to adher-
ence are somewhat crude, they clearly indicate that
cost-effectiveness in real life can be quite different. We
are therefore cautious to interpret our estimates only
within the context of “strict adherence to the guide-
lines.”On the other hand,we observed that the relative
positions of the scenarios remained largely unchanged
in these analyses.
During the course of this study, a revision of the hy-
pertension guidelines appeared.24 This update pro-
posed a similar screening strategy as in Figure 1 but
with using a lower minimal entry-level criterion, 140/
90 mm Hg instead of 160/95 mm Hg. In addition, the
minimum BP level for drug treatment was lowered to
140/90 mm Hg for patients with an absolute mortality
risk over 10 years over 20%. As these changes imple-
ment someof ourbest scenarios, it is tobe expected that
the updated guidelines will have improved cost-
effectiveness.
What can we say about other standards?25-27 Com-
pared to others, the Dutch guidelines are quite conser-
vative. Our results indicate that they might be in fact
too conservative and miss important health gains by
setting the levels for screening and treatment too high.
The British guidelines recommendBPmeasurement of
all adults at least every 5 years until the age of 80 years,
as well as annual remeasurements of those with high-
normal values (135–139/85–89 mm Hg) or with high
readings at anypreviousmeasurement.25 This selection
of persons is akin to scenario “any,” the scenario that
we found to be the most expensive and most liberal.
Assuming the UK population is not too different from
the Dutch population, this suggests that using a more
selective set of screening criteria could improve the
cost-effectiveness of the British guidelines. For some
groups, the new US guidelines26 prescribe drug treat-
ment at BP levels as lowas 130/80mmHg. It is possible
to adapt our methodology to these guidelines, so that
the model can be rerun on US or British data. The
Dutch model defined a level of 160/90 mm Hg under
which the effect of drug treatment on risk is considered
to be zero. This parameter would obviously need to be
adjusted to bring out the risk-reducing effects of drug
therapy for people with lower risks.
There are many reasons why the optimal country-
specific guidelines may differ from each other. Large
international differences exist in cardiovascular risk
profiles,28,29 demographic composition, pricing ofmed-
ication, policies regarding drug treatment, organiza-
tion of the health care system, disease incidences, dis-
ease costs, and so on. The existence of an optimal set of
universally applicable guidelines is unlikely. Our
methodprovides away to account for the risk profile of
a population, as well as for characteristics of the local
health services. In general, both characteristics need to
be taken into account in the development of
guidelines.
CONCLUSION
Appropriate targeting of hypertension guidelines to
a population and critical appraisal of the entire screen-
ing procedure can enhance cost-effectiveness of this
screening. The method as described is flexible and en-
ables appropriate targeting of hypertension guidelines
to a population and critical appraisal of the entire
screening procedure. Its added value in the improve-
ment of screening procedures for other health
problems deserves additional study.
APPENDIX
This appendix contains further details of the simulation
model designed for this study. The general idea is as follows.
Themodel describes the route taken by an individual patient
under a given scenario for screening and subsequent treat-
ment of hypertension. Individual outcomes vary as a result of
differences in individual risk factors, differences between
scenarios, differences that emanate from the random alloca-
tion to treatment andnontreatment groups (only for scenarios
modeling under- and over-treatment), and differences that
occur as random variation in the simulated BP measure-
ments. The model assumed that screening occurs in the year
2000. Themodel estimatesmortality andmorbidity risks and
all costs for all individuals during the period 2000–2009. Ag-
gregation over individuals and time allows for the estimation
of costs andhealth effects in subgroups and in the population
at large. Costs and health effects can also be compared across
different scenarios for screening and subsequent interven-
tion. Systematic comparison of different scenarios yields in-
sight into the most optimal scenarios for the population at
hand.
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The model consists of 4 major components:
1. Adata set of persons representative for thepopulation
2. A set procedures for screening and subsequent treat-
ment of hypertension (scenarios)
3. A riskmodel for futuremortality and disease for every
person
4. Aset of rules for calculating costs andhealthoutcomes
The text below provides additional details of each
component.
Cardiovascular risk factor data from theMORGEN study12
(ages 20–59, n = 13,742) and the Rotterdam study13 (ages 55+,
n = 7,983) were used. A combined data set was constructed,
but several practical problems had to be dealt with. First, we
observed large differences (about 8 mm Hg) between the
mean DBP levels of the MORGEN and Rotterdam data at the
ages of overlap (55–59 years), whereas no such differences
were present for SBP. Because it is desirable that theBP levels
connect at the joint ages and because the DBP levels of the
Rotterdam data were relatively low (about 73 mm Hg), we
corrected for this difference by adding 8 mm Hg to all SBP
measurements from theRotterdamstudy.A2ndproblemwas
that dismissing incomplete records from the Rotterdam data
would result in a severe reduction of the available information
(from 7983 to 4360 individuals). We addressed this problem
by multivariate imputation. Incomplete continuous factors
(SBP, DBP, LDL/HDL ratio) were imputed by linear regression,
incomplete binary factors (smoking, diabetes, cardiovascular
history, familial cardiovascular disease, left-ventricular hy-
pertrophy, alreadybeing treated forhypertension, use of alco-
hol) were imputed by logistic regression, and incomplete
polytomous variables (BMI classes) were imputed by
polytomous regression. We used the incompatible Gibbs
sampler30 as implemented in Multivariate Imputation by
Chained Equations (MICE).31 We used single imputation,
which allows for valid point estimates, but not for confidence
intervals or statistical tests. A 3rd problem was that neither
studyhad collecteddirect information about the frequencyof
visits to the physician. We constructed a logistic regression
model using the 34,152 respondents older than 20 years,
taken from the Dutch Health Interview Survey 1990–1995 of
the Netherlands Central Bureau of Statistics. The model pre-
dicts the probability of visiting the physician during the past
year given age, sex, smoking, diabetes, cardiovascular his-
tory, being treated for hypertension, and BMI. The value of a
random draw from the binomial distribution, with the indi-
vidual predicted probability as its parameter, was added to
the combined data set. A redraw of 11,983 respondents was
made from the combined data set such that that age and sex
distributions corresponded to the Dutch population of 20
years or older per 1 January 2000. Each person in the micro-
simulation sample thus corresponded to 1000 real people in
the population.
Procedures for screening and subsequent treatment of hy-
pertension, such as those presented in Figure 1 or variations
therefore, were implemented in a computer program. For ev-
ery person in the microsimulation sample, the program cal-
culates if the person enters the screening procedure, how
many times the BP is measured, the height of each BP mea-
surement, the diagnosed hypertension status, and whether
intervention by drug treatment is indicated.
Themodel uses the Framingham risk equations15 to simu-
late individual patient histories over a period of 10 years.
These equations predict the probability of cardiovascular
mortality and morbidity as a function of BP, age, sex, smok-
ing, LDL/HDL ratio, diabetes, and left-ventricular hypertro-
phy. Table 3 provides a description of the 6 endpoints of the
Framingham equations. To assess howwell the Framingham
equations apply to the Dutch population, the predicted 5-
year incidence was compared to longitudinal data from the
University of Amsterdam (1985–1994, 95,000 person
years).32 Except for some minor deviations, it turned out the
Framingham equations closely predicted the observedDutch
5-year incidence, butminor adjustments were needed for the
older groups. Table 3 provides age-adjusted calibration fac-
tors. The goal of drug treatment is to lower future mortality
and disease risks. Per endpoint, a risk reduction factor is esti-
mated based on an extensive meta-analysis on the direct
treatment effect on each endpoint.16 For example, 751 in-
farcts occurred in treatment groups (n = 163,453) and 884 in-
farcts occurred in control groups (n = 161,250), so the risk re-
duction of treatment is (751/163,453)/(884/161,250) = 0.838
(i.e., the number of infarcts reduces by 16.2% as a result of
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Table 3 Endpoints of the Framingham Equations, Correction Factors Used to Calibrate the Equations to the
Dutch Incidence Data, and the Estimated Risk Reduction
Name Endpoint Description Calibration Factor Calibration Group Risk Reduction
CHDD Coronary heart disease death None 0.857
CVDD Cardiovascular disease death None 0.803
CHD Coronary heart disease 1.02549^(age-60) 60+ females 0.838
MI Myocardial infarction 1.04091^(age-60) 60+ females 0.838
STROKE Stroke, including transient ischemic attack 1.03888^(age-50) 50+ males 0.657
1.03811^(age-50) 50+ females
CVD Cardiovascular disease None 0.775
Note: Symbol “^” stands for the power operator.
treatment). The last column of Table 3 lists the risk reduction
factors used by the simulation model.
After the individual risk on each Framingham endpoint is
calculated, the model derives 7 intermediate health out-
comes and 3mortality and 4morbiditymeasures. Table 4 de-
fines how each of these is expressed in terms of Framingham
endpoints. The termMORT in the definition of “OtherDeath”
is not from the Framingham study but represents the survival
probability (all death causes) per age and sex, calculated from
the life tables over the year 1998 for the Netherlands.33 The
other columns of Table 4 list the costs per year of an event in
euros in the 1st year and in each subsequent year,10 as well as
the utility values used to calculate the QALY per person.21
The individual mortality and disease probabilities are ag-
gregated to the population and subgroup levels. The model
calculates the absolute incidence as 1000 times the sum of
probabilities over all persons in the sample. The NNT is the
number of patientswho shouldbe treated toprevent 1 cardio-
vascular event and is calculated as the inverse of the risk dif-
ference in the treated group. The NNS is the number of peo-
ple who must be screened (and treated if indicated) to
prevent 1 cardiovascular event20 and is calculated as the in-
verse of the risk difference in the entire population. Risk dif-
ference is expressed relative to the null model (scenario
“freeze”). The life expectancy of each survivor is calculated
from his or her age and sex using life tables.33 To account for
increased mortality in the diseased, the mortality quotient is
multiplied by the risk of dying when having the disease rela-
tive to the risk of dying when healthy. The following relative
risks were estimated from the MORGEN study and used in
the calculation of life expectancy: MI (male 2.5, female 4.0),
CHDR (male 2.4, female 3.8), STROKE (2.0), and CVDR (2.0).
Quality-adjusted life expectancy was calculated in the same
way, with the difference that partial instead of full years are
counted when morbidity occurs. The utility values per mor-
bidity state are given in Table 3. Healthy life expectancy was
calculated by counting only the healthy, here defined as non-
CVD, life years.
A much more extensive report (in Dutch) on the model
and its results has been written by the authors34 and is avail-
able upon request.
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